The results are surprising relative to the well-known function of HDAC inhibitors as having antitumor activities, including reduced proliferation [172], increased differentiation/apoptosis [173], and that a number of them are on the clinical development pipeline for anti-cancer therapeutics [174-177]. This evidence concerns the gene HDAC9 and cancer.